New Registry Will Track Real-World Efficacy of Approved Alzheimer’s Treatments

A new national registry, sponsored by the Alzheimer’s Association, will track real-world outcomes data for Alzheimer’s patients receiving FDA-approved treatments for the disease, including the antiamyloid antibody Aduhelm.
Source: Drug Industry Daily